Search Results
Your search for ,wAS matches 27583 pages
Showing 19251 - 19300Pertuzumab-Containing Regimens Compared for Neoadjuvant Treatment in Early Breast Cancer
In patients with HER2-positive early breast cancer, pathologic complete response rates after neoadjuvant therapy were higher with docetaxel plus carboplatin plus trastuzumab (Herceptin) plus pertuzumab (Perjeta), or TCH+P, than with ado-trastuzumab emtansine (Kadcyla) plus pertuzumab, or T-DM1+P,...
Expert Point of View: Nancy E. Davidson, MD
Nancy E. Davidson, MD, the Hillman Professor of Oncology and Director of the University of Pittsburgh Cancer Institute in Philadelphia, was the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) study’s formal discussant. With this analysis, she noted, the EBCTCG has “reinforced the long...
EBCTCG Analysis Identifies Recurrence Risk by Tumor Subgroup in Estrogen Receptor–Positive Breast Cancer
The risk of recurrence in estrogen receptor–positive breast cancer is known to continue after 5 years, but just how much is that risk once endocrine therapy is stopped? The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) has concluded it is “appreciable,” with distant recurrences...
Analysis of Cerebrospinal Fluid for D-2-Hydroxyglutarate May Detect Malignant Brain Tumors Nonsurgically
When a brain tumor is suspected, its presence is usually confirmed by anatomic imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). But through imaging, not much about the tumor molecularly can be learned. Surgery and a biopsy are necessary to get a glimpse of the cancer...
The Age of the Atomic Hematologists/Oncologists
Every longstanding culture has ages: The Minoans were followed by the Mycenaeans and, later, the Hellenistic peoples. And so it is with hematology/oncology. A descriptive age dominated predominately by histopathologists was followed by an age of experimentalists. Development of the atomic bombs...
Assessment of Fitness, Function, and Quality of Life Essential in Treatment of Older Patients With CLL
Significant progress has been made in the past 2 decades in the care of patients with chronic lymphocytic leukemia (CLL). Recently, the therapeutic armamentarium has expanded for such patients with the introduction of new targeted agents. CLL is predominantly a disease of the elderly, with a...
Improved Survival Reported With Prostate Radiation Therapy Plus Androgen-Deprivation Therapy in Metastatic Prostate Cancer
The addition of prostate external-beam radiation therapy to androgen-deprivation therapy was associated with prolonged overall survival in men with newly diagnosed metastatic prostate cancer, according to a National Cancer Database analysis reported by Rusthoven et al in the Journal of Clinical...
Factors Associated With Chemotherapy-Induced Peripheral Neuropathy in Older Patients
In an analysis of the linked Southwest Oncology Group–Medicare databases reported by Hershman et al in the Journal of Clinical Oncology, an increased risk of peripheral neuropathy in older patients receiving taxane therapy was associated with increasing age and a history of diabetes in...
Study Finds Regorafenib Increases Progression-Free Survival in Advanced Gastric Cancer
The multikinase inhibitor regorafenib (Stivarga) prolonged progression-free survival vs placebo in patients with previously treated advanced gastric carcinoma, in a phase II trial reported in the Journal of Clinical Oncology by Pavlakis et al. A regional difference in treatment effect was observed. ...
Expert Point of View: David R. Spigel, MD
“These are outstanding results,” commented formal discussant of this trial David R. Spigel, MD, of the Sarah Cannon Research Institute, Nashville, Tennessee. In melanoma, the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) vs nivolumab alone vs ipilimumab alone found superior...
Combination of Nivolumab and Ipilimumab Moves Forward in NSCLC
How best to combine new immunotherapies is a burning question in oncology. A new study in the CheckMate series suggests that nivolumab (Opdivo) and ipilimumab (Yervoy) can be safely and effectively combined as first-line treatment of advanced non–small cell lung cancer (NSCLC),1 but further study...
Primary Care Visits Result in More Colorectal Cancer Screening, Better Follow-up
People who visit their primary care physicians are more likely to get potentially life-saving colon cancer screenings and follow-up on abnormal stool blood test results—even in health systems that heavily promote mail-in home stool blood tests that don’t require a doctor visit, a study...
No Advantage With Cyclophosphamide/Methotrexate Maintenance in Hormone Receptor–Negative Early Breast Cancer, but Subgroup May Benefit
Low-dose oral cyclophosphamide plus methotrexate maintenance therapy yielded no disease-free survival benefit in women with hormone receptor–negative early breast cancer, according to the phase III International Breast Cancer Study Group (IBCSG) 22-00 trial. Some evidence of benefit was...
Tasquinimod Improves Radiographic PFS but Not OS in Metastatic Castration-Resistant Prostate Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Sternberg et al found that tasquinimod, an oral therapy targeting components of the tumor microenvironment, increased radiographic progression-free survival but not overall survival vs placebo in men with chemotherapy-naive...
Study Finds Adding Olaratumab to Doxorubicin Improves Survival in Advanced Soft-Tissue Sarcoma
The addition of olaratumab, an anti–platelet-derived growth factor receptor alpha (anti–PDGFRα) antibody, to doxorubicin resulted in prolonged progression-free and overall survival in the phase II evaluation of patients with advanced soft-tissue sarcoma, according to findings...
French Phase III Trial Shows No Benefit of Adding Zoledronate to Chemotherapy and Surgery in Osteosarcoma
In the French phase III OS2006 trial reported by Piperno-Neumann et al in The Lancet Oncology, the addition of zoledronate to chemotherapy and surgery provided no event-free survival benefit in the treatment of patients with newly diagnosed high-grade osteosarcoma. Study Details In the open-label ...
Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL
In the phase III GADOLIN trial reported in The Lancet Oncology, Sehn et al found that adding the anti-CD20 antibody obinutuzumab (Gazyva) to bendamustine (Bendeka, Treanda) increased progression-free survival in patients with rituximab-refractory indolent non-Hodgkin lymphoma (NHL). Outcomes in...
Women With High-Grade Cervical Intraepithelial Neoplasia Have Long-Term Increased Risk for HPV-Related Anal, Vulvar, and Vaginal Cancers
Although high-risk human papillomavirus (HPV) is essential for developing high-grade cervical intraepithelial neoplasia (CIN2 and CIN3) and has also been associated with noncervical anogenital cancers, little is known about the long-term risk for anal, vulvar, and vaginal cancer following a...
FDA Approves Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C Virus Infection
On June 28, the U.S. Food and Drug Administration (FDA) approved a fixed-dose combination of sofosbuvir, 400 mg, plus velpatasvir, 100 mg (Epclusa) to treat adult patients with chronic hepatitis C virus (HCV) either with or without cirrhosis. For patients with moderate to severe cirrhosis...
Study Finds Addition of High-Dose Cytarabine to Immunochemotherapy Before Transplant Improves Outcomes in Younger Patients With MCL
The phase III European MCL Younger trial has shown that adding high-dose cytarabine to immunochemotherapy prior to autologous stem cell transplantation (ASCT) increased the time to treatment failure among patients with mantle cell lymphoma (MCL) aged ≤ 65 years. The results were reported by...
No Overall Advantage to Adding Pertuzumab to Chemotherapy in Platinum-Resistant Ovarian Cancer, but Subgroup May Benefit
According to the European phase III PENELOPE trial reported in the Journal of Clinical Oncology, Kurzeder et al found that adding pertuzumab (Perjeta) to investigator’s choice of chemotherapy did not improve progression-free survival in women with low-HER3 mRNA–expressing...
Ipilimumab Combined With Antigen-Specific Cytotoxic T Lymphocytes May Be of Benefit in Metastatic Melanoma
In a study reported in the Journal of Clinical Oncology by Chapuis et al, concurrent use of cytotoxic T lymphocyte (CTL) antigen-4 (CTLA-4) blockade with ipilimumab (Yervoy) and adoptively transferred antigen-specific CTLs produced enduring responses in patients with stage IV melanoma. Study...
CAP, IASLC, and AMP Seek Public Comments on Revised Lung Cancer Molecular Testing Guideline
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence-based guideline, “Molecular Testing Guideline for Selection of...
Influence of Microbiota of Breast Tissue on the Development of Cancers
Bacteria that have the potential to abet breast cancer are present in the breasts of cancer patients, while beneficial bacteria are more abundant in healthy breasts, where they may actually be protecting women from cancer, according to Gregor Reid, PhD, of the Lawson Health Research Institute, and...
Reduced-Intensity Transplantation With Haploidentical Related Donors vs HLA-Matched Sibling Donors in Patients With Lymphoma
In an analysis of the observational data base of the Center for International Blood and Marrow Transplant Research reported in the Journal of Clinical Oncology, Ghosh et al found that lymphoma patients undergoing reduced-intensity conditioning had similar outcomes with related-donor haploidentical...
Is Nivolumab Active in Recurrent Small Cell Lung Cancer?
In the phase I/II CheckMate 032 study, nivolumab (Opdivo) alone and with ipilimumab (Yervoy) demonstrated activity in patients with small cell lung cancer (SCLC) progressing after at least one previous platinum regimen, as reported in The Lancet Oncology by Antonia et al. Study Details In the...
I Was Not Shown Compassion by My Medical Team
At my last screening mammogram in 2015, nothing seemed out of the ordinary. The technician took the usual four x-rays of my breasts, and I was told I could leave. So it was especially shocking to get a phone call from the radiologist a week later telling me that I had to come back for an additional ...
Precision Medicine Clinical Trial for Metastatic Pancreatic Cancer Now Open at Multiple Sites
The first clinical trial to compare standard-of-care chemotherapy with molecularly tailored therapy (also known as precision medicine) for metastatic pancreatic cancer is now enrolling patients at multiple sites around the country. Patients who have been treated with one round of chemotherapy for...
Four-Biomarker Panel Identified for Chronic Graft-vs-Host Disease
In a study reported in the Journal of Clinical Oncology, Jeffrey Yu, MD, of the Indiana University School of Medicine, Indianapolis, and colleagues identified a four-biomarker panel that was predictive of chronic graft-vs-host disease after allogeneic hematopoietic cell transplantation. Discovery...
Increased Risk of Gallbladder Cancer May Be Associated With Consuming Large Amounts of Sweetened Beverages
A large prospective Swedish study reported by Susanna C. Larsson, PhD, of the Unit of Nutritional Epidemiology at the Institute of Environmental Medicine at Karolinska Institutet in Stockholm, Sweden, and colleagues found a 2.2-fold increased risk of gallbladder cancer in people who consumed two or ...
Adding Adjuvant Oxaliplatin to Fluoropyrimidine May Be of Benefit in Deficient Mismatch Repair Colon Cancer
In a French retrospective study reported by David Tougeron, MD, PhD, of Poitiers University Hospital, Poitiers, France, and colleagues in the Journal of the National Cancer Institute, the addition of adjuvant oxaliplatin to fluoropyrimidine treatment improved disease-free survival in patients with...
Retroviral Replicating Vector That Delivers Cytosine Deaminase to Cancer Cells Active in Recurrent Glioblastoma
A phase I study by Timothy F. Cloughesy, MD, Director of the Neuro-Oncology Program at the UCLA Jonsson Comprehensive Cancer Center, and colleagues published in Science Translational Medicine investigated the effectiveness of vocimagene amiretrorepvec (Toca 511), an experimental nonlytic,...
AMA Announces Board of Trustees for 2016–2017
The American Medical Association (AMA) has introduced the 21 members of its Board of Trustees for the coming year, following elections held during the Annual Meeting of the AMA House of Delegates. Andrew W. Gurman, MD, an orthopedic hand surgeon, was sworn in as the 171st President of the AMA. In...
Surgery and Radiation Therapy Remain Standard of Care for Managing Ductal Carcinoma in Situ
A review of more than 50 studies (many randomized controlled trials) concluded that surgery and radiation therapy “remain standard-of-care treatment options” in the management of ductal carcinoma in situ.1 The review continues the widely reported discussion on managing ductal carcinoma in situ,...
Taubman Prize Jointly Awarded to Suzanne L. Topalian, MD, and Jedd D. Wolchok, MD, PhD, for Groundbreaking Work in Cancer Immunotherapy
Two clinician-scientists whose groundbreaking work has shown how the human body’s own immune system can fend off cancer will share the 2016 $100,000 Taubman Prize for Excellence in Translational Medical Science, the University of Michigan’s A. Alfred Taubman Medical Research Institute announced....
Something Happened
Over the years, my patients have been my most important teachers. I’ve learned so much from them about human nature and the resilience of the human spirit. When my time came to pass through the fire and confront the same challenges they and their families face so bravely and with such compassion, ...
Ohio State Names Timothy Pawlik, MD, MPH, PhD, Chair of Surgery and Chair for Cancer Research
The Ohio State University Wexner Medical Center has appointed a nationally recognized surgeon and liver cancer expert to lead its surgical and surgical oncology programs. Timothy Pawlik, MD, MPH, PhD, will be the Chair of the Medical Center’s Department of Surgery, as well as The Urban Meyer III...
Black Cohosh
Scientific Name: Cimicifuga racemosa Common Names: Black snakeroot, rattlesnake root, squawroot, bugbane, bugwort Brand Names: Remifemin, Menofem, Klimadynon Overview A perennial plant native to the eastern United States and Canada, black cohosh root was used by Native Americans to treat colds,...
Inside Knowledge From a Cancer Survivor
Curtis Pesmen is a well-regarded writer who has authored six books of nonfiction as well as numerous articles for publications such as Esquire and The New York Times. He also has served as founding editor of LIVESTRONG Quarterly and often speaks and writes on patient advocacy. Shortly after...
A Journalist’s Cancer Saga
Readers of the recently published memoir A Series of Catastrophes & Miracles: A True Story of Love, Science, and Cancer find out that the book has a happy ending on the cover page of chapter 1. Spoiler: I lived, writes the author, Mary Elizabeth Williams, an acclaimed journalist with a list...
An Exotic Journey Into Immunotherapy
In his new book, Sharks Get Cancer, Mole Rats Don’t: How Animals Could Hold the Key to Unlocking Cancer Immunity in Humans, James S. Welsh, MD, examines a wide array of animal and human biologic phenomena, searching for clues that might help us unlock the full power of the human immune system....
Newly Launched Genomic Data Commons to Facilitate Data and Clinical Information Sharing
The Genomic Data Commons (GDC), a unified data system that promotes sharing of genomic and clinical data among researchers, was launched on June 6 with a visit from Vice President Joe Biden to the operations center at the University of Chicago. An initiative of the National Cancer Institute (NCI),...
St. Jude Children’s Research Hospital Names Michael Dyer, PhD, Chair of Developmental Neurobiology
St. Jude Children’s Research Hospital has named Michael Dyer, PhD, Chair of the Department of Developmental Neurobiology. “A true visionary in his field, Dr. Dyer is a remarkable scientist who has worked tirelessly to unravel some of the long-held mysteries of childhood cancer,” said James R....
Peter S. Conti, MD, PhD, Receives SNMMI 2016 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science
Peter S. Conti, MD, PhD, Professor of Radiology, Pharmaceutical Sciences, and Biomedical Engineering, and Director of the Molecular Imaging Center at the Keck School of Medicine at the University of Southern California, has been named the 2016 recipient of the prestigious Paul C. Aebersold Award....
Moonshot Program for … Compassion
A 65-year-old patient with widely metastatic pancreatic cancer was emergently transferred to our facility in the early hours of the morning with free air suggestive of a perforated viscus. The patient is from a small town several hundred miles away from our academic center, which can be quite...
Vanguard Practices Support Sharing Big Data With CancerLinQ™
CancerLinQ LLC, recently announced that it has completed agreements with 36 vanguard oncology practices from around the country to begin implementing the tool. According to physicians at the vanguard practices, gaining access to the experience of oncology practices across the country motivated...
Initiative to Modernize Eligibility Criteria for Clinical Trials Launched
ASCO and Friends of Cancer Research (Friends) have launched a collaborative effort to modernize eligibility criteria to promote greater patient participation in cancer clinical trials. Although it is important for defining the population under study and ensuring patient safety, overly strict...
Meet Thomas G. Roberts, Jr, MD
Thomas G. Roberts, Jr, MD, is Managing Member at Farallon Capital Management, LLC and Chair of the Conquer Cancer Foundation of ASCO Board of Directors and Executive Committee. What led you to oncology prior to your career in finance? TGR: As an intern at Massachusetts General Hospital, I was...
Clinical Conversations: Attendee Questions From the Cancer Survivorship Symposium
The inaugural Cancer Survivorship Symposium, held in January 2016, drew more than 800 attendees across the cancer-care spectrum—far exceeding the goal of 500 attendees. As a way to continue the discussion from the meeting, several faculty members responded to questions from General Sessions 5 and...
ASCO Endows Young Investigator Award in Honor of Society Founder Jane Cooke Wright, MD
For the first time in ASCO’s history, the Society has endowed its own Young Investigator Award (YIA), illustrating its continued commitment to investing in the future of cancer research. Ongoing support of this kind will ensure that the Conquer Cancer Foundation (CCF), ASCO’s philanthropic arm, is...
